Wall Street Analysts Predict an 119.28% Upside in Alpha Cognition Inc. (ACOG): Here's What You Should Know
Alpha Cognition Announces Publication of U.S. Patent Application for Benzgalantamine for Treating Persistent Post-Concussion Symptoms
Alpha Cognition Announces Publication Of US Patent Application Covering Benzgalantamine For Treating Persistent Post-Concussion Symptoms
Alpha Cognition (ACOG) Q3 2026 Earnings Call Transcript
Alpha Cognition Inc. Common Stock Q3 2026 Earnings Call Summary
What Alpha Cognition (ACOG) Said on Its Q3 Earnings Call
Alpha Cognition (NASDAQ:ACOG) Posts Q3 Beat as ZUNVEYL Demand Builds
Alpha Cognition Inc. Reports Third Quarter 2026 Financial Results and Provides Operational Update
Alpha Cognition Inc. (ACOG) Q3 2026 Earnings Call Transcript
Alpha Cognition Q3 2026 Earnings Call Transcript
Alpha Cognition Q3 EPS $(0.35) Misses $(0.34) Estimate, Sales $7.777M Beat $7.040M Estimate
Alpha Cognition Strengthens Its Board of Directors with Appointment of Caren Deardorf
Alpha Cognition to Participate in Upcoming Investor Events
Alpha Cognition to Report Third Quarter 2026 Financial Results and Provide Business Update
Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®
Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care
Alpha Cognition Announces Data From Its 180-Day Analysis Of Its CONVERGE PRogram For Patients Receiving ZUNVEYL, Donepezil, Galantamine Or Rivastigmine
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.